Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Malignant Cancer

Interventions

DRUG

SHR-2022 Injection

SHR-2022 Injection is administered by intravenous (IV) infusion

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06131216 - Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter